Immunogenicity of CAR T cells in cancer therapy.
Dimitrios L Wagner, Enrico Fritsche, Michael A Pulsipher...
https://pubmed.ncbi.nlm.nih.gov/33633361/Actively Recruiting
Led by Sichuan University · Updated on 2026-08-13
40
Participants Needed
1
Research Sites
78 weeks
Total Duration
Researchers are evaluating the safety, tolerability, and early antitumor effects of dual-targeting VEGFR1PD-L1 chimeric antigen receptor CAR T-cells in adults with solid tumors that have spread to the pleural, peritoneal, or leptomeningeal areas. These metastases have very poor outlooks due to their unique immune environment and physical barriers, limiting treatment options. This Phase I open-label study uses a dose-escalation and expansion design to find the best dose and assess initial effects of this novel approach. Participants receive a single infusion of their own genetically modified T-cells targeting VEGFR1 and PD-L1. Administration routes depend on the metastatic site intrapleural or intraperitoneal for pleural or peritoneal metastases, and intrathecal for leptomeningeal metastases. The study includes two cohorts with different dosing strategies and escalation designs. After determining the recommended phase II dose RP2D, an expansion phase will further assess safety and preliminary efficacy. During the study, participants are monitored for dose-limiting toxicities and adverse events up to six months after infusion. The research team evaluates tumor response, progression-free survival, overall survival, and CAR-T cell persistence in blood and local fluids. Neurological symptoms and tumor cell clearance in cerebrospinal fluid are also assessed. Participation includes clinical evaluations, laboratory tests, and follow-up visits for up to five years to track long-term outcomes.
CONDITIONS
Dual-targeting VEGFR1 and PD-L1 CAR-T for Pleural, Peritoneal, or Leptomeningeal Metastases
X
XIA HE, Ph.D
G
Ge Gao, Ph.D
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Sichuan University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 21 days post-infusion for dose-limiting toxicity observation
Participants receive a single infusion of VEGFR1/PD-L1 dual-targeting CAR-T cells via intrapleural, intraperitoneal, or intrathecal routes, depending on the metastatic site. The dose is increased stepwise to determine the best tolerated dose.
Regular monitoring visits during the 21-day observation period
Duration - Approximately 2 years
After the best dose is identified, participants receive the recommended phase II dose to further assess safety and preliminary efficacy.
Scheduled follow-up visits during this period
Duration - Up to 5 years
Participants are monitored for up to 5 years to assess tumor response, survival, CAR-T cell persistence, and neurological outcomes.
Periodic visits and assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Dimitrios L Wagner, Enrico Fritsche, Michael A Pulsipher...
https://pubmed.ncbi.nlm.nih.gov/33633361/P K Cheema, R L Burkes
https://pubmed.ncbi.nlm.nih.gov/23559882/Sichuan University
Lead Sponsor